300 Bleomycin Etoposide and Cisplatin Bep Therapy
300 Bleomycin Etoposide and Cisplatin Bep Therapy
300 Bleomycin Etoposide and Cisplatin Bep Therapy
TREATMENT:
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their
independent medical judgement, to consider each patients individual clinical circumstances.
Treatment with etoposide and CISplatin is administered on days 1-5, and treatment with bleomycin is
administered on days 1, 8 and 15 of a 21 day cycle.
For good risk patients - 3 cycles are administered,
For intermediate to poor risk patients - 4 cycles are administered
Order
a
1 1, 8 and 15 Bleomycin 30,000 International Units IV Bolus
(30mg) or IMb
2 1-5 Etoposide 100mg/m2 IV infusion 1000ml 0.9% NaCl over 60 minutesc
3 1-5 CISplatin 20mg/m2 IV infusion 1000ml 0.9% NaCl over 1 hour
(Pre hydration therapy required) d
Bleomycin dosing may be referred to in international units (IU) or in mg. 1,000 international units = 1mg
aThe total cumulative dose of bleomycin should NOT exceed 400,000 international units (400mg).
The risk of pulmonary toxicity increases beyond a cumulative dose of 300,000 international units (300mg).
bFor IM injection dose is dissolved in up to 5ml 0.9% NaCl. If pain occurs at the site of injection a 1% solution of lignocaine may be used as a solvent (6)
ELIGIBILITY:
Indications as above
ECOG status 0-3
Published: 08/04/2016
NCCP Regimen: BEP Therapy Version number: 5
Review: 28/11/2024
Tumour Group: Genitourinary/Gynaecology ISMO Contributor: Dr Maccon Keane
Page 1 of 5
NCCP Regimen Code: 00300
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted
approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of
individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is
subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
NCCP Chemotherapy Regimen
EXCLUSIONS:
Hypersensitivity to bleomycin, etoposide, CISplatin or any of the excipients.
Bleomycin is contraindicated in patients with acute pulmonary infection or chest X rays
suggesting diffuse fibrotic changes or greatly reduced lung function
CISplatin
o Pre existing neuropathies ≥ grade 2
o Creatinine clearance < 40 mL/min
o Significant hearing impairment/tinnitus
Severe liver impairment (etoposide)
PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist.
TESTS:
Baseline tests:
FBC, renal and liver profile, creatinine
Pulmonary function tests (PFTs) and Chest X-ray prior to bleomycin
Consider sperm banking for appropriate patients prior to initiation of therapy
Consider Audiometry testing
Regular tests:
FBC weekly during treatment
Renal and liver profile, creatinine prior to each treatment cycle
Chest X-ray prior to each cycle
PFTs as clinically indicated
Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed
by the supervising Consultant.
DOSE MODIFICATIONS:
Any dose modification should be discussed with a Consultant
Published: 08/04/2016
NCCP Regimen: BEP Therapy Version number: 5
Review: 28/11/2024
Tumour Group: Genitourinary/Gynaecology ISMO Contributor: Dr Maccon Keane
Page 2 of 5
NCCP Regimen Code: 00300
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted
approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of
individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is
subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
NCCP Chemotherapy Regimen
Haematological:
Delay and dose reductions are not recommended as the efficacy of this treatment may be greatly
compromised
All delays to treatment must be approved by prescribing consultant.
Prophylactic use of G-CSF is not recommended.
G-CSF is indicated in patients receiving their second or subsequent cycle of BEP who have had an episode of
neutropenic fever or who have not recovered their neutrophil count by Day 5.
SUPPORTIVE CARE:
EMETOGENIC POTENTIAL:
Days 1-5 High
Days, 8 15 Minimal (Refer to local policy).
Published: 08/04/2016
NCCP Regimen: BEP Therapy Version number: 5
Review: 28/11/2024
Tumour Group: Genitourinary/Gynaecology ISMO Contributor: Dr Maccon Keane
Page 3 of 5
NCCP Regimen Code: 00300
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted
approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of
individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is
subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
NCCP Chemotherapy Regimen
PREMEDICATIONS:
Hydration prior to CISplatin administration (Reference local policy or see recommendations above).
DRUG INTERACTIONS:
Bleomycin causes sensitization of lung tissue to oxygen. If oxygen is required the use of low concentration
(e.g. 25%) is recommended. Fluid replacement should be carefully monitored with emphasis on
administration of colloid rather than crystalloid to avoid interstitial pulmonary oedema.
CISplatin may potentiate the nephrotoxic and ototoxic effects of loop diuretics and aminoglycosides so
concurrent use should be avoided.
Concomitant CISplatin therapy is associated with reduced total body clearance of etoposide.
CYP3A4 inducers may increase the clearance of etoposide.
CYP3A4 and p-gp inhibitors may decrease the clearance of etoposide
Current drug interaction databases should be consulted for more information
ATC CODE:
Bleomycin L01DC01
CISplatin L01XA01
Etoposide L01CB01
Published: 08/04/2016
NCCP Regimen: BEP Therapy Version number: 5
Review: 28/11/2024
Tumour Group: Genitourinary/Gynaecology ISMO Contributor: Dr Maccon Keane
Page 4 of 5
NCCP Regimen Code: 00300
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted
approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of
individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is
subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens
NCCP Chemotherapy Regimen
REFERENCES:
1. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-
prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;
7:387-91
2. Williams S, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with CISplatin,
bleomycin, and either vinblastine or etoposide. N Engl J Med, 1987; 316: 1435-1440
3. de Wit R, Roberts JT, Wilkinson P, et al. Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles
and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III
study. Proc Am Soc Clin Oncol 2000; 19a:326a (abstract 1281).
4. Nichols et al. Randomized comparison of CISplatin and etoposide and either bleomycin or ifosfamide in
treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group,
Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; Vol 16 (No.4):
1287-1293
5. Williams SD, Blessing JA, Hatch KD et al. Chemotherapy of advanced dysgerminoma: trials of the
Gynecologic Oncology Group. J Clin Oncol 1991; 9(11):1950-1955.
6. Bleomycin, etoposide, and CISplatin (BEP) chemotherapy for germ cell tumors. UptoDate. January 2016
7. Bleo-Kyowa Summary of Product Characteristics Accessed September 2017. Available at
https://www.medicines.org.uk/emc/product/4263/smpc
8. Cisplatin (Eloxatin®) Summary of Product Characteristics HPRA.Last updated: 11/03/2019. Accessed
August 2019 Available at:
https://www.hpra.ie/img/uploaded/swedocuments/Final%20approved%20SPC%20PA0822.199.001.pdf
9. Etoposide 20 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics. HPRA Last
updated: 29/07/2019 Accessed November 2019 Available at:
https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2059-036-001_29072019103821.pdf
10. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
Available at http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-
cytotoxics.pdf
11. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network.
Available at http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-
cytotoxics.pdf
12. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V1
2018. Available at:
https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp%20antiemetic%20classific
ation%20document%20v1%202018.pdf
Published: 08/04/2016
NCCP Regimen: BEP Therapy Version number: 5
Review: 28/11/2024
Tumour Group: Genitourinary/Gynaecology ISMO Contributor: Dr Maccon Keane
Page 5 of 5
NCCP Regimen Code: 00300
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted
approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of
individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is
subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens